Title of article :
Hepatitis B Seroconversion Rate After Primary Immunization Series with Newly Introduced Pentavalent Vaccine: A Report of Local Study in Alborz Province, Iran, 2016
Author/Authors :
Arjmand, Reza Department of Pediatric - Emam Ali Hospital - Alborz University of Medical Sciences, Karaj , Golami, Mehri Alborz University of Medical Sciences, Karaj , Shirvani, Fariba Pediatric Infections Research Center - Research Institute for Children’s Health - Shahid Beheshti University of Medical Sciences, Tehran , Pourrostami, Kumars Department of Pediatric - Emam Ali Hospital - Alborz University of Medical Sciences, Karaj , Safari, Omid Department of Pediatric - Emam Ali Hospital - Alborz University of Medical Sciences, Karaj , Elahimehr, Nasrin Department of Pediatric - Emam Ali Hospital - Alborz University of Medical Sciences, Karaj , Nikkhah, Saeed Department of Pediatric - Emam Ali Hospital - Alborz University of Medical Sciences, Karaj , Zahmatkesh, Ehsan Department of Pediatric - Emam Ali Hospital - Alborz University of Medical Sciences, Karaj , Qorbani, Mostafa Non-Communicable Diseases Research Center - Alborz University of Medical Sciences, Karaj , Najafi Tavana, Esfandiar Department of Pediatric - Emam Ali Hospital - Alborz University of Medical Sciences, Karaj
Abstract :
Background: Since November 2014, pentavalent vaccine is available in Iran. This vaccine should be injected into all Iranian children
at two, four, and six months after birth.
Objectives: There is little information on the immunogenicity of this vaccine against hepatitis B (HB) in Iranian children; therefore,
the current study aimed at investigating the vaccine efficacy six months after administration of the last dose.
Methods: A total of 400 blood samples were collected from one-year-old children referred to Karaj healthcare centers, Alborz
province, Iran. After sampling, checklists of demographic information were completed. Blood samples were sent to the laboratory
to determine antibody titer by CMIA (chemiluminescent microparticle immunoassay). Statistical analysis was conducted by
Stata and SVY software.
Results: Overall, 393 (98.3%) children (95% confidence interval (CI): 96.03% - 99.57%) had a protective IgG titer of > 10 mIU/mL, while it
was < 10 mIU/mL in seven (95% CI: 0.5% - 3.1%) subjects. Geometricmeantiter was 419.66 mIU/mL (95% CI: 380.52 - 462.82). Anti-HBsAb
titer was not associated with gender and the type of milk feeding.
Conclusions: The seroprotection of HB vaccine in a pentavalent combination vaccine in Iran, six months after three doses of vaccination,
was acceptable.
